SPH KDL HEALTH(SHANGHAI) PHARMACEUTICAL CO.,LTD.

Pharmaceuticals, Biotechnology and Life Sciences

Targets set1.5°CNet-Zero: Targets set

SBTI ID

40019705

Informations générales

Localisation

China

Asia

Secteur d'activité

Pharmaceuticals, Biotechnology and Life Sciences

Type d'organisation

Corporate

Dernière mise à jour

08/01/2026

Objectifs à court terme (Near-Term)
Engagement de réduction des émissions à horizon 2035

Statut

Targets set

Classification

1.5°C

Année cible

2035

Progression vers l'objectif55%
2015 (année de référence)2035
Objectifs à long terme (Long-Term)
Engagement de réduction des émissions à horizon 2050

Statut

Targets set

Classification

1.5°C

Année cible

2050

Progression vers l'objectif31%
2015 (année de référence)2050
Description complète des objectifs

Overall Net-Zero Target: SPH KDL HEALTH(SHANGHAI) PHARMACEUTICAL CO.,LTD. commits to achieve net-zero greenhouse gas emissions across the value chain by 2050. Near-Term Targets: SPH KDL HEALTH(SHANGHAI) PHARMACEUTICAL CO.,LTD. commits to reduce absolute scope 1 and 2 GHG emissions 63.0% by 2035 from a 2024 base year. SPH KDL HEALTH(SHANGHAI) PHARMACEUTICAL CO.,LTD. also commits to reduce absolute scope 3 GHG emissions 37.5% within the same timeframe. Long-Term Targets: SPH KDL HEALTH(SHANGHAI) PHARMACEUTICAL CO.,LTD. commits to reduce absolute scope scope 1, 2 and 3 GHG emissions 90.0% by 2050 from a 2024 base year. Within this target, SPH KDL HEALTH(SHANGHAI) PHARMACEUTICAL CO.,LTD. commits to reduce absolute scope 1 and 2 GHG emissions 90.0% by 2050 from a 2024 base year and reduce absolute scope 3 GHG emissions 90.0% within the same timeframe.

Net-Zero

Statut

Targets set

Année cible

2050

Progression31%
Classification détaillée

The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C

Source : Science Based Targets initiative | Données publiques